Astrana Health (NASDAQ:ASTH) Hits New 1-Year Low – Should You Sell?

Astrana Health, Inc. (NASDAQ:ASTH)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $19.19 and last traded at $19.6380, with a volume of 143632 shares traded. The stock had previously closed at $21.10.

Wall Street Analysts Forecast Growth

ASTH has been the topic of several research analyst reports. Needham & Company LLC initiated coverage on Astrana Health in a research note on Friday, December 12th. They issued a “buy” rating and a $28.00 price objective on the stock. Barclays reduced their price target on shares of Astrana Health from $36.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Monday, November 24th. Jefferies Financial Group reissued a “buy” rating on shares of Astrana Health in a research report on Tuesday, November 25th. Zacks Research upgraded shares of Astrana Health from a “strong sell” rating to a “hold” rating in a report on Monday, January 12th. Finally, TD Cowen decreased their price target on shares of Astrana Health from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Astrana Health presently has an average rating of “Moderate Buy” and a consensus price target of $40.78.

Astrana Health Price Performance

The company has a market cap of $1.08 billion, a price-to-earnings ratio of 101.16, a P/E/G ratio of 0.55 and a beta of 0.90. The company’s 50-day simple moving average is $24.30 and its 200-day simple moving average is $26.77. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.40 and a quick ratio of 1.40.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors have recently added to or reduced their stakes in ASTH. 325 Capital LLC grew its stake in shares of Astrana Health by 34.6% during the third quarter. 325 Capital LLC now owns 1,193,953 shares of the company’s stock valued at $33,849,000 after acquiring an additional 307,037 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Astrana Health by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,028,168 shares of the company’s stock worth $25,513,000 after acquiring an additional 12,212 shares in the last quarter. SteelPeak Wealth LLC boosted its holdings in Astrana Health by 7.8% in the third quarter. SteelPeak Wealth LLC now owns 579,937 shares of the company’s stock valued at $16,441,000 after purchasing an additional 41,761 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Astrana Health by 19.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 500,527 shares of the company’s stock valued at $14,190,000 after purchasing an additional 80,465 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC increased its holdings in Astrana Health by 0.5% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 450,465 shares of the company’s stock worth $12,343,000 after purchasing an additional 2,084 shares during the last quarter. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.